Unpacking the bold — and the bluster — in Trump’s plan to bring down drug prices image

STAT, July 23, 2018
by Erin Mershon, quoting Rachel Sachs (Academic Fellow Alumna)


Read the full article

From the article:

The administration says the proposal will save Medicare money, which could translate into lower premiums. It will also mean lower co-pays for any beneficiary who might need a new drug when it first comes onto the market, since those payments are based on how much a drug costs. The administration is hoping to finalize the regulation this fall, after a mandatory comment period.

The proposal is limited. It would only be in effect for a few months, and it only applies to new drugs that fall into the right regulatory category. It’s tough to estimate how big of an impact the proposal will have, since it’s hard to guess how many new drugs might launch in the future and at what prices.

It’s notable, however, because it is one of the few drug-pricing proposals on the administration’s list that actually takes aim at drug maker prices, said Rachel Sachs, an associate professor at the Washington University in St. Louis School of Law.

Read more here!

fda health care finance health care reform health law policy pharmaceuticals rachel sachs